Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Neuro-OncologyOpen Access

P05.06.b Clinical Usefulness of MGMT Promoter Methylation Quantification in GBM Patients Treated With Chemo-Radiation Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBarbara MuoioSESamantha EpistolioFPFrancesco Polinelli

Discussion

Loading...

Member takes

Overview

Analysis shows MGMT methylation levels may predict outcomes in glioblastoma, suggesting EpiDirect® could improve diagnostics.

Key Points

  • EpiDirect® successfully identified 37.8% of cases with MGMT promoter methylation in glioblastoma patients treated with chemo-radiation.
  • Using EpiDirect®, a high concordance was observed with traditional methods, achieving a Cohen index of 0.829.
  • Despite improved quantification ability, MGMT methylation levels did not show clinical relevance in predicting overall survival.
  • The study analyzed 119 GBM cases to verify the effectiveness of different methylation testing methodologies.

Cite This Study

Muoio et al. (2025) studied this question.

synapsesocial.com/papers/68e24e6bd6d66a53c2473a85https://doi.org/10.1093/neuonc/noaf193.211
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P05.16.B DEFINING THE OPTIMAL MGMT METHYLATION CUTOFF AND ITS CORRELATION WITH SIGNIFICANT GENETIC ALTERATIONS2025
  2. 2The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma2025 · 4 citations
  3. 3IDH wild-type glioblastoma: Predictive value of standard-of-care (SOC) MRI for establishing MGMT promoter methylation status2025 · 1 citations
  4. 4P03.16.A MGMT PROMOTER METHYLATION PREDICTION IN HIGH GRADE GLIOMAS USING CONVENTIONAL MRI AND MACHINE LEARNING SEGMENTATIONS2025
  5. 5MOLECULAR MARKERS IN PREDICTING THE OUTCOME OF DIFFUSE GLIOMA GRADE 4 TREATMENT2025